Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF‑related apoptosis‑inducing ligand

Chen,Hui; Li,Liang‑Qing; Pan,Dun

doi:10.3892/ol.2015.3807

Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF‑related apoptosis‑inducing ligand

Authors:
- Hui Chen
- Liang‑Qing Li
- Dun Pan
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Clinical Medical College, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: October 15, 2015 https://doi.org/10.3892/ol.2015.3807
Pages: 3732-3736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the effect of geldanamycin (GA) on the treatment of human gastric carcinomas and to investigate the molecular mechanism that provides the basis for the combination of GA with the tumor necrosis factor (TNF)‑related apoptosis‑inducing ligand (TRAIL) induction strategy. The expression of target proteins at the mRNA level was determined using reverse transcription‑polymerase chain reaction (RT‑PCR), and apoptosis was evaluated with the terminal deoxynucleotidyl transferase mediated digoxigenin‑dUTP nick‑end labeling and Annexin V/propidium iodide (PI) staining methods. Phosphorylation of targeted kinases was studied using immunocytochemistry methods, and malignant phenotypes were studied using in vitro assays. GA treatment inhibits proliferation, migration and invasion, and induces apoptosis in human gastric cancer SGC‑7901 cells, most likely by decreasing the expression of B‑RAF and by phosphorylation of protein kinase B (AKT) and ERK. The inhibitory role of AKT in TRAIL regulation holds considerable potential for achieving a synergic effect in clinical therapy, using a combination of GA treatment and TRAIL induction. The present study provides a basis for the future application of heat shock protein 90 (Hsp90) inhibitors, such as GA, in the clinical treatment of gastric cancer, particularly in combination therapies with TRAIL inducers.

View Figures

View References

1	Solit DB and Rosen N: Hsp90: A novel target for cancer therapy. Curr Top Med Chem. 6:1205–1214. 2006. View Article : Google Scholar : PubMed/NCBI
2	Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
3	Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K and Giles FJ: Targeting HSP90 for cancer therapy. Br J Cancer. 100:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
4	Sidera K and Patsavoudi E: HSP90 inhibitors: Current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 9:1–20. 2014.PubMed/NCBI
5	Ferrarini M, Heltai S, Zocchi MR and Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 51:613–619. 1992. View Article : Google Scholar : PubMed/NCBI
6	Neckers L and Neckers K: Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs. 7:277–288. 2002. View Article : Google Scholar : PubMed/NCBI
7	Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Höhfeld J and Patterson C: The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 3:93–96. 2001. View Article : Google Scholar : PubMed/NCBI
8	Goetz MP, Toft DO, Ames MM and Erlichman C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 14:1169–1176. 2003. View Article : Google Scholar : PubMed/NCBI
9	Schulte TW, Blagosklonny MV, Ingui C and Neckers L: Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 270:24585–24588. 1995. View Article : Google Scholar : PubMed/NCBI
10	Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J and Neckers LM: Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol. 16:5839–5845. 1996. View Article : Google Scholar : PubMed/NCBI
11	Neri LM, Borgatti P, Capitani S and Martelli AM: The nuclear phosphoinositide 3-kinase/AKT pathway: A new second messenger system. Biochim Biophys Acta. 1584:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kumar A, Rajendran V, Sethumadhavan R and Purohit R: AKT kinase pathway: A leading target in cancer research. ScientificWorldJournal. 2013:7561342013. View Article : Google Scholar : PubMed/NCBI
13	Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P and Rosen N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 277:39858–39866. 2002. View Article : Google Scholar : PubMed/NCBI
14	Ma W and Quirion R: The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin Ther Targets. 9:699–713. 2005. View Article : Google Scholar : PubMed/NCBI
15	Lee JT Jr and McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 16:486–507. 2002. View Article : Google Scholar : PubMed/NCBI
16	Dou F, Yuan LD and Zhu JJ: Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim Biophys Sin (Shanghai). 37:501–505. 2005. View Article : Google Scholar : PubMed/NCBI
17	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
19	Song JJ and Lee YJ: Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal. 20:892–906. 2008. View Article : Google Scholar : PubMed/NCBI
20	Xu J, Zhou JY, Wei WZ and Wu GS: Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PloS One. 5:e102262010. View Article : Google Scholar : PubMed/NCBI
21	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl): 5–11. 2002. View Article : Google Scholar : PubMed/NCBI
22	Chen M, Xu J and Zhao J: Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901. Nan Fang Yi Ke Da Xue Xue Bao. 33:271–275. 2013.(In Chinese). PubMed/NCBI
23	Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, et al: Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
24	Redlak MJ and Miller TA: Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis. Dig Dis Sci. 56:323–329. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hede K: Gastric cancer: Trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 101:1306–1307. 2009. View Article : Google Scholar : PubMed/NCBI
26	Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU and Pavletich NP: Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell. 89:239–250. 1997. View Article : Google Scholar : PubMed/NCBI
27	Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995. View Article : Google Scholar : PubMed/NCBI
28	Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang Y, Ye S, Wu S, Zhong G, Ren J, et al: MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci. 9:680–692. 2013. View Article : Google Scholar : PubMed/NCBI
29	Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 16:1882009. View Article : Google Scholar
30	da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P and Marais R: Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65:10686–10691. 2005. View Article : Google Scholar : PubMed/NCBI
31	Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D and Rosen N: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA. 103:57–62. 2006. View Article : Google Scholar : PubMed/NCBI
32	Neckers L and Neckers K: Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs. 10:137–149. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl). 82:488–499. 2004. View Article : Google Scholar : PubMed/NCBI
34	Koga F, Xu WP, Karpova TS, McNally JG, Baron R and Neckers L: Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA. 103:11318–11322. 2006. View Article : Google Scholar : PubMed/NCBI
35	Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
36	Hostein I, Robertson D, DiStefano F, Workman P and Clarke PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-Allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61:4003–4009. 2001.PubMed/NCBI
37	Powers MV, Clarke PA and Workman P: Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 14:250–262. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
39	Jhaveri K, Taldone T, Modi S and Chiosis G: Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755. 2012. View Article : Google Scholar : PubMed/NCBI